GSK/ChemoCentryx Crohn’s Failure May Sink Hefty Phase III Program
This article was originally published in The Pink Sheet Daily
Executive Summary
SHIELD-1 failure puts the entire 2,500-patient plus Phase III clinical program in limbo as GSK rethinks its Crohn’s disease approach and partner ChemoCentryx’s stock loses close to half its value.
You may also be interested in...
Deals Of The Week Watches An Unlikely HCIT Partnership: GSK & Community Care of North Carolina
GSK and CCNC, a non-profit network of health care providers, are developing a medication management analytics system that could get them into the health care IT business. For GSK, the main goal is to learn about changing dynamics of health care delivery systems, in a venture that is entirely independent of the company’s core drug business.
ChemoCentryx Regains Crohn’s Candidate Vercirnon From GSK
GSK will continue development of a rheumatoid arthritis candidate optioned from ChemoCentryx in 2011 and is expected to decide before year’s end on whether to license a Phase II candidate for renal vasculitis from the California biotech.
ViiV Secures Its First New Drug Approval With Tivicay
The HIV specialist, a joint venture between GSK, Pfizer and Shionogi, will launch the once-daily integrase inhibitor Tivicay, priced slightly higher than Merck’s Isentress and about on par with Gilead’s Stribild when Tivicay is combined with backbone therapy.